Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Comment by PTBaileyon Jan 25, 2022 11:34am
108 Views
Post# 34358195

RE:PtBailey..,

RE:PtBailey..,I don't think the delay is with the TSX even though they have to approave everthing eventually. Part of it is finalizing details with ethics committee, at Scientia which like CMAX they only meet once a week which drags out the process when they want more info.

This is a post from the CI FB site from last Wed...
Last week the Human Research Ethics Committee (HREC) wanted further details on the animal studies we conducted on rats dogs and sheep as Salzman only gave them a brief summary rather than the full version. Last week and over the weekend he compiled far more than they could ever need from our BARDA application and other research and has handed it off to them.
They meet on Wednesdays but it's just them meeting not us so the reams of material won't be gone over until after the meeting which would be now I guess so, until they go over it all (and there is a lot to go over if they bother to do more than a cursory examination) there isn't much more to add.

<< Previous
Bullboard Posts
Next >>